annb0t
Top 20
Mesoblast Limited MESO recently announced that the FDA has granted a Rare Pediatric Disease (RPD) designation to its allogeneic cell therapy, Revascor (rexlemestrocel-L), for treating children with congenital heart disease. Shares of the company were up 20.9% in after-hours trading on Jan 18, following the announcement of the news.
The RPD designation is granted by the FDA to medicines that treat serious or life-threatening diseases, which usually affect children of all ages. Upon potential app...
>>> Read more: Mesoblast (MESO) Up on Rare Pediatric Disease Tag for Heart Drug
The RPD designation is granted by the FDA to medicines that treat serious or life-threatening diseases, which usually affect children of all ages. Upon potential app...
>>> Read more: Mesoblast (MESO) Up on Rare Pediatric Disease Tag for Heart Drug
